Familial Hypercholesterolemia Clinical Trials in Beijing, Beijing Municipality
6 recruitingBeijing, Beijing Municipality, China
Showing 1–6 of 6 trials
Recruiting
Phase 3
Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia - Heterozygous
Novartis Pharmaceuticals60 enrolled66 locationsNCT06597019
Recruiting
Phase 2Phase 3
A Study of Enlicitide Decanoate (MK-0616, an Oral PCSK9 Inhibitor) in Children and Adolescents With Heterozygous Familial Hypercholesterolemia (MK-0616-029)
Heterozygous Familial Hypercholesterolemia (HeFH)
Merck Sharp & Dohme LLC153 enrolled26 locationsNCT07058077
Recruiting
Phase 3
IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Innovent Biologics (Suzhou) Co. Ltd.198 enrolled1 locationNCT07473960
Recruiting
Phase 3
A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia
Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.760 enrolled2 locationsNCT07421297
Recruiting
Phase 3
Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
Familial Hypercholesterolemia - Homozygous
Novartis Pharmaceuticals9 enrolled18 locationsNCT06597006
Recruiting
Phase 3
A Study on Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia
Primary hypercholesterolemiaMetabolic DiseaseDyslipidemias+4 more
Hasten Biopharmaceutical Co., Ltd.210 enrolled18 locationsNCT06568471